Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MDM2 proto-oncogene, E3 ubiquitin protein ligase | Starlite/ChEMBL | No references |
Homo sapiens | MDM4, p53 regulator | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0026 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0038 | 0.3146 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0038 | 0.3146 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0026 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0064 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0063 | 0.9718 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.2864 | 0.2864 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0064 | 1 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0026 | 0 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0063 | 0.9718 | 0.9706 |
Onchocerca volvulus | 0.0064 | 1 | 1 | |
Trichomonas vaginalis | conserved hypothetical protein | 0.0026 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0063 | 0.9718 | 0.9718 |
Plasmodium vivax | hypothetical protein, conserved | 0.0026 | 0 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0026 | 0 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0026 | 0 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0064 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0026 | 0 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0026 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0064 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0063 | 0.9718 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0064 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0026 | 0 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0038 | 0.3146 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0064 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0038 | 0.3146 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0064 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0026 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0038 | 0.3146 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0026 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0063 | 0.9718 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 699.9 nM | BindingDB_Patents: Time Resolved Fluorescence Energy Transfer (TR-FRET) Assay. The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfer (or Foerster resonance energy transfer) describes an energy transfer between donor and acceptor fluorescent molecules. For this assay, human MDM2 protein (amino acids 2-188) and human MDM4 protein (amino acids 2-185), tagged with a C-terminal biotin moiety, are used in combination with a Europium labeled streptavidin (Perkin Elmer, Inc., Waltham, MA, USA) serving as the donor fluorophore. The p53 derived, Cy5 labeled peptide Cy5-TFSDLWKLL (p53 aa18-26) is the energy acceptor. Upon excitation of the donor molecule at 340nm, binding interaction between MDM2 or MDM4 and the p53 peptide induces energy transfer and enhanced response at the acceptor emission wavelength at 665 nm. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.